1. Home
  2. NNNN vs ENOV Comparison

NNNN vs ENOV Comparison

Compare NNNN & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NNNN
  • ENOV
  • Stock Information
  • Founded
  • NNNN 2021
  • ENOV 1995
  • Country
  • NNNN Germany
  • ENOV United States
  • Employees
  • NNNN N/A
  • ENOV N/A
  • Industry
  • NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • ENOV Fluid Controls
  • Sector
  • NNNN Health Care
  • ENOV Industrials
  • Exchange
  • NNNN Nasdaq
  • ENOV Nasdaq
  • Market Cap
  • NNNN 2.2B
  • ENOV 1.8B
  • IPO Year
  • NNNN 2025
  • ENOV 2008
  • Fundamental
  • Price
  • NNNN $23.92
  • ENOV $32.58
  • Analyst Decision
  • NNNN
  • ENOV Strong Buy
  • Analyst Count
  • NNNN 0
  • ENOV 6
  • Target Price
  • NNNN N/A
  • ENOV $51.00
  • AVG Volume (30 Days)
  • NNNN 76.5K
  • ENOV 617.7K
  • Earning Date
  • NNNN 11-07-2025
  • ENOV 11-06-2025
  • Dividend Yield
  • NNNN N/A
  • ENOV N/A
  • EPS Growth
  • NNNN N/A
  • ENOV N/A
  • EPS
  • NNNN 0.06
  • ENOV N/A
  • Revenue
  • NNNN $8,185,146.00
  • ENOV $2,189,576,000.00
  • Revenue This Year
  • NNNN N/A
  • ENOV $9.13
  • Revenue Next Year
  • NNNN N/A
  • ENOV $6.39
  • P/E Ratio
  • NNNN $442.46
  • ENOV N/A
  • Revenue Growth
  • NNNN 21.95
  • ENOV 14.40
  • 52 Week Low
  • NNNN $5.18
  • ENOV $25.47
  • 52 Week High
  • NNNN $55.65
  • ENOV $49.83
  • Technical
  • Relative Strength Index (RSI)
  • NNNN 35.64
  • ENOV 56.80
  • Support Level
  • NNNN $26.05
  • ENOV $29.00
  • Resistance Level
  • NNNN $30.65
  • ENOV $34.28
  • Average True Range (ATR)
  • NNNN 2.72
  • ENOV 1.07
  • MACD
  • NNNN -0.11
  • ENOV 0.17
  • Stochastic Oscillator
  • NNNN 19.80
  • ENOV 67.71

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

About ENOV Enovis Corporation

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Share on Social Networks: